| Session: Pathogen-directed Therapeutics |
| Chair: "Gary" Guilin Qiao |
|
1400 - 1430
|
Subramanyam Swaminathan, Brookhaven National Laboratory
|
|
|
Mode of VAMP Recognition by Botulinum Neurotoxin F and Its Implication in Drug Design
|
|
1430 - 1500
|
Patrick McNutt, USAMRICD
|
|
|
Development of Embryonic Stem Cell-Derived Neurons as Moderate-Throughput Discovery Platform for Botulinum Inhibitors
|
|
1500 - 1530
|
Break
|
|
1530 - 1600
|
Yuan-Ping Pang, Mayo Clinic
|
|
|
Potent New Small-Molecule Inhibitor of Botulinum Neurotoxin Serotype A
Endopeptidase Developed by Synthesis-Based Computer-Aided Molecular Design
|
|
1600 - 1630
|
Jon Davis, US Army Medical Research Institute of Infectious Diseases
|
|
|
Development of Small Molecule Inhibitors of Botulinum neurotoxin serotype A
|
| Return to previous page |